Patent · US Active

Protein sustained-release injectable formulation

US10093726B2 · kind B2 · utility

0Cited by

0References

1Claims

0Family size

Assignee

ESBATech, an Alcon Biomedical Research Unit LLC · CH

Inventors

Lutz Asmus · Geneva, CH
Michael Möller · Cham, DE
Robert Gurny · Geneva, CH
John P. A. Grimshaw · Zürich, CH

Key dates

Filing date	Aug 24, 2016
Grant date	Oct 9, 2018
Priority date	—
Expiry date	Aug 24, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.